BioPharma Resources

Drug Trial Radar · NCT05035212

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 38,861 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

38,861

Actual

Start

Aug 31, 2021

Primary completion

Jan 18, 2027

Study completion Jan 18, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This study is an extension of the efficacy study and was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 2 years: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 18 months. * The study will be conducted in the United States and Argentina. Substudy B: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 1 year: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 18 months. * The study will be conducted in Argentina. Substudy C: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of either 3 or 4 years: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Participants will receive either placebo or a second dose of RSVpreF approximately 3 or 4 years after receiving the initial dose of RSVpreF in the main efficacy study. * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States and Canada.

Conditions

  • Lower Respiratory Tract Illness

Interventions

  • RSVpreFBiological

    RSV vaccine (RSVpreF)

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Study: Number of first episode of RSV-associated lower respiratory tract illness (LRTI-RSV) in the first RSV seasonTime frame: From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)
  2. Efficacy Study: Proportion of participants reporting prompted local reactions within 7-days after vaccinationTime frame: Within 7 days after vaccination
  3. Efficacy Study: Proportion of participants reporting prompted systemic events within 7-days after vaccinationTime frame: Within 7 days after vaccination
  4. Efficacy Study: Proportion of participants reporting AE within 1-month after vaccinationTime frame: Within 1 month after vaccination (up to 35 days)
  5. Efficacy Study: Proportion of participants reporting SAE throughout the studyTime frame: Throughout the study duration (an average of 30 months)
  6. Efficacy Study: Proportion of participants reporting NDCMC throughout the studyTime frame: Throughout the study duration (an average of 30 months)
  7. SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreFTime frame: Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSA
  8. SSA: Proportion of participants reporting prompted local reactions within 7-days after revaccinationTime frame: Within 7 days after revaccination
  9. SSA: Proportion of participants reporting prompted systemic events within 7-days after revaccinationTime frame: Within 7 days after revaccination
  10. SSA: Proportion of participants reporting AE within 1-month after revaccinationTime frame: Within 1 month after revaccination (up to 35 days)
  11. SSA: Proportion of participants reporting SAE throughout the studyTime frame: Throughout the study duration (approximately 18 months)
  12. SSA: Proportion of participants reporting NDCMC throughout the studyTime frame: Throughout the study duration (approximately 18 months)
  13. SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreFTime frame: Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSB
  14. SSB: Proportion of participants reporting prompted local reactions within 7-days after revaccinationTime frame: Within 7 days after revaccination
  15. SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccinationTime frame: SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccination
  16. SSB: Proportion of participants reporting AE within 1-month after revaccinationTime frame: Within 1 month after revaccination (up to 35 days)
  17. SSB: Proportion of participants reporting SAE throughout the studyTime frame: Throughout the study duration (approximately 18 months)
  18. SSB: Proportion of participants reporting NDCMC throughout the studyTime frame: Throughout the study duration (approximately 18 months)
  19. SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF or placebo in SSC (Year 3)Time frame: 1 month after revaccination in SSC (Year 3)
  20. SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study (preS2) and revaccination in SSC (Year 3)Time frame: At preseason 2 (preS2) after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 3)
  21. SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study and revaccination in SSC (Year 3)Time frame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 3)
  22. SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF or placebo in SSC (Year 4)Time frame: 1 month after revaccination in SSC (Year 4)
  23. SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study (preS2) and revaccination in SSC (Year 4)Time frame: At preseason 2 (preS2) after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 4)
  24. SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study and revaccination in SSC (Year 4)Time frame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 4)
  25. SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 3)Time frame: Within 7 days after revaccination
  26. SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 4)Time frame: Within 7 days after revaccination
  27. SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 3)Time frame: Within 7 days after revaccination
  28. SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 4)Time frame: Within 7 days after revaccination
  29. SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 3)Time frame: Within 1 month after revaccination (up to 35 days)
  30. SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 4)Time frame: Within 1 month after revaccination (up to 35 days)
  31. SSC: Proportion of participants reporting SAE after revaccination (Year 3)Time frame: Following revaccination and throughout the study duration (approximately 24 months)
  32. SSC: Proportion of participants reporting SAE after revaccination (Year 4)Time frame: Following revaccination and throughout the study duration (approximately 12 months)
  33. SSC: Proportion of participants reporting NDCMC after revaccination (Year 3)Time frame: Following revaccination and throughout the study duration (approximately 24 months)
  34. SSC: Proportion of participants reporting NDCMC after revaccination (Year 4)Time frame: Following revaccination and throughout the study duration (approximately 12 months)

Locations

263 sites in 7 countries. Site status is shown where the registry gives one.

  • St. Vincent's Birmingham (Pharmacy)

    Birmingham, Alabama

  • St. Vincent's Birmingham

    Birmingham, Alabama

  • Medical Affiliated Research Center

    Huntsville, Alabama

  • Lenzmeier Family Medicine / Avacare

    Glendale, Arizona

  • Phoenix Clinical LLC

    Phoenix, Arizona

  • HOPE Research Institute

    Phoenix, Arizona

  • The Pain Center of Arizona

    Phoenix, Arizona

  • HOPE Research Institute

    Phoenix, Arizona

  • Cognitive Clinical Trials, LLC

    Phoenix, Arizona

  • Headlands Research - Scottsdale

    Scottsdale, Arizona

  • Alliance for Multispecialty Research, LLC

    Tempe, Arizona

  • HOPE Research Institute

    Tempe, Arizona

  • Noble Clinical Research

    Tucson, Arizona

  • The Institute for Liver Health dba Arizona Clinical Trials

    Tucson, Arizona

  • Hope Clinical Research

    Canoga Park, California

  • eStudySite

    Chula Vista, California

  • Benchmark Research

    Colton, California

  • West Coast Research

    Dublin, California

  • Marvel Clinical Research 002, LLC

    Huntington Beach, California

  • Chemidox Clinical Trials

    Lancaster, California

  • Ark Clinical Research

    Long Beach, California

  • Downtown L.A. Research Center, Inc.

    Los Angeles, California

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California

  • Clinica mi Salud by Focil Med

    Oxnard, California

  • De Silva Medical Inc

    Palmdale, California

  • Empire Clinical Research

    Pomona, California

  • Paradigm Clinical Research Center

    Redding, California

  • Artemis Institute for Clinical Research

    Riverside, California

  • Benchmark Research

    Sacramento, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • California Research Foundation

    San Diego, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Lynn Institute of Denver

    Aurora, Colorado

  • Tekton Research LLC

    Longmont, Colorado

  • Clinical Research Consulting

    Milford, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • JEM Research Institute

    Atlantis, Florida

  • IDEAL Clinical Research

    Aventura, Florida

  • Innovative Research of West Florida

    Clearwater, Florida

  • Invictus Clinical Research Group, LLC

    Coconut Creek, Florida

Showing 40 of 263 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.